Mark Goldsmith
CEO
Mark Goldsmith is the CEO of Revolution Medicines, where he has championed the development of daraxonrasib, an experimental drug that targets specific cancer mutations and has shown promise in clinical trials.
Global Media Ratings
Dominance
0.00%
Persistence
0 wks
Reach
0
Power
0$
Sentiment
0.00
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Greece:
Mark Goldsmith recalled that most scientists thought their method would destroy normal cells.
6
Debbie Orcutt
Andrew Nixon
Brian Wolpin
Lei Zheng
Kevan Shokat
Anna Berkenblit
Pranati Perati
Marty Makary
Kathimerini: Πειραματικό χάπι γεννά ελπίδες για έναν από τους πιο θανατηφόρους καρκίνους